40 completed, 6 not yet recruiting, 2 recruiting, 1 unknown. 19 Phase 2, 17 Phase 3, 9 Phase 1, 4 Phase 4, 2 Not applicable.
Follow PT Bio Farma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster - Human Papillomavirus (HPV) Infection | Phase 3 | Not yet recruiting | PT Bio Farma | 266 | 2026-10-01 | 2026-09-17 |
| Study Interchangeability Hep-B Vaccine Administered at Birth Dose In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine | Phase 3 | Not yet recruiting | PT Bio Farma | 270 | 2026-10-01 | 2026-10-02 |
| A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations LipovaxinS4-EAH (Middle Dose), LipovaksinS4-EAH (High Dose), Placebo - Tuberculosis, TB Infection | Phase 1 | Not yet recruiting | PT Bio Farma | 60 | 2026-08-01 | 2026-06-15 |
| Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma) - Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Withdrawn | PT Bio Farma | 2025-12-01 | 2025-06-05 | |
| Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2), Placebo (Sterile Water) - Poliomyelitis | Phase 2 | Recruiting | PATH | 675 | 2025-11-11 | 2026-01-09 |
| Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) In-House Recombinant Hepatitis B (Bio Farma) vaccine, Registered Hepatitis B vaccine recombinant (Engerix-B) - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Not yet recruiting | PT Bio Farma | 540 | 2025-09-01 | 2025-06-06 |
| Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV Antibody Typhoid Vaccine | Not yet recruiting | PT Bio Farma | 624 | 2025-06-15 | 2025-06-03 | |
| Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A, DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B, Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)® - Vaccine Adverse Reaction, Vaccine Reaction | Phase 1 / Phase 2 | Not yet recruiting | PT Bio Farma | 465 | 2025-03-01 | 2024-11-15 |
| Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination COVID-19 | Completed | PT Bio Farma | 1208 | 2023-12-18 | 2024-11-15 | |
| Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3) - Poliomyelitis | Phase 2 | Recruiting | PATH | 1532 | 2023-12-05 | 2026-05-11 |
| Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine SARS-CoV-2 Subunit Recombinant Protein Vaccine - COVID-19 | Phase 2 | Completed | PT Bio Farma | 150 | 2023-07-25 | 2025-06-05 |
| Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients Enoxaparin sodium injection - Safety Issues, Effect of Drug | Phase 4 | Completed | PT Bio Farma | 220 | 2023-06-01 | 2025-06-06 |
| Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 2 | Completed | PATH | 2232 | 2023-03-27 | 2026-09-25 |
| Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age SARS-CoV-2 subunit protein recombinant vaccine - COVID-19 | Phase 2 | Completed | PT Bio Farma | 150 | 2023-02-28 | 2025-06-03 |
| Post Marketing Surveillance of Diphtheria Antitoxin (DAT) Diphtheria Antitoxin - Safety Issues | Phase 4 | Completed | PT Bio Farma | 68 | 2023-01-31 | 2023-11-18 |
| Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung Medwell Preventive Care Application, Manual Records - Diabetes Mellitus, Type 2 | Not applicable | Unknown | PT Bio Farma | 160 | 2022-11-12 | 2023-04-19 |
| Post Authorization Safety Study Moderna COVID-19 Primary Vaccine Moderna COVID-19 Vaccine - COVID-19 | Completed | PT Bio Farma | 1284 | 2022-11-03 | 2023-11-18 | |
| Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Completed | PT Bio Farma | 1050 | 2022-10-09 | 2025-06-03 |
| Booster Study of COVID-19 Protein Subunit Recombinant Vaccine SARS-CoV-2 subunit protein recombinant vaccine, Active Comparator - COVID-19 | Phase 2 | Completed | PT Bio Farma | 696 | 2022-09-01 | 2025-06-03 |
| Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator - COVID-19 | Phase 3 | Completed | PT Bio Farma | 4050 | 2022-06-07 | 2023-11-29 |
Showing 20 of 50. Sign in to see all of them.
COVID-19 (10) · Hepatitis B (4) · Poliomyelitis (4) · Infections (3) · Papillomavirus Infections (2) · Diabetes Mellitus, Type 2 (1) · Measles (1) · Rubella (1) · Tuberculosis (1) · Virus Diseases (1)
Vaccines (5) · Vi polysaccharide vaccine, typhoid (3) · Hepatitis B Vaccines (2) · 2019-nCoV Vaccine mRNA-1273 (1) · COVID-19 Vaccines (1) · Diphtheria Antitoxin (1) · Engerix-B (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1) · HibTITER protein, Haemophilus influenzae (1) · Influenza Vaccines (1) · Pneumococcal Vaccines (1) · Poliovirus Vaccine, Inactivated (1) · Poliovirus Vaccine, Oral (1) · RV3 rotavirus vaccine (1) · Vaccines, Synthetic (1)
Indonesia (44) · Bangladesh (2) · Panama (2)
Julitasari Sundoro, MD (4) · Kusnandi Rusmil, PhD (4) · Bernie Endyarni, MD (3) · Eddy Fadlyana, MD (3) · Bernie E Medise, MD (2) · Dominicus Husada, MD (2) · Yetty Movieta Nency, MD (2) · Asrawati Asrawati, MD (1) · Bambang Widyantoro, Ph.D (1) · Bernie Medise, MD (1) · Cahya Satria, MD (1) · Dominicus Husada, Dr (1) · Dominicus Husada, Professor (1) · Eddy Fadliyana (1)
PMID 26686508, PMID 29551225, PMID 29804542, PMID 31862195, PMID 32004693, PMID 33059607, PMID 36495882, PMID 37616221, PMID 38297337, PMID 38575433, PMID 40381203